Novartis Ag (NVS) Short term Debt (2009 - 2026)
Novartis Ag (NVS) posted Short term Debt of $9.6 billion for Q2 2026, up 50563.16% sequentially from -$19.0 million in Q1 2026, and up 15.32% YoY from $8.3 billion in Q2 2025.
Novartis Ag (NVS) Short term Debt (2009 - 2026) Analysis & Trends
Novartis Ag has reported Short term Debt for 18 years, with the latest figure at $9.6 billion in Q2 2026.
- Quarterly Short term Debt rose 15.32% year-over-year to $9.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.6 billion (up 15.32% YoY) and the FY2025 annual result came in at $5.6 billion, down 31.95% from the prior year.
- Short term Debt advanced to $9.6 billion in Q2 2026 per NVS's latest filing, from -$19.0 million in the prior quarter.
- Over five years, Short term Debt peaked at $9.6 billion in Q2 2026 and troughed at -$19.0 million in Q1 2026.
- A 5-year average of $5.3 billion and a median of $6.2 billion in 2023 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2024 and 2025: Short term Debt plunged 100.16% in 2024, then surged 56120.0% in 2025.
- Over 5 years, Short term Debt stood at $5.9 billion in 2022, then increased by 4.11% to $6.2 billion in 2023, then slumped by 100.16% to -$10.0 million in 2024, then soared by 56120.0% to $5.6 billion in 2025, then surged by 71.15% to $9.6 billion in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $9.6 billion, -$19.0 million, and $5.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.59 Bn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | 5.60 Bn |
| Sep 30, 2025 | -9.00 Mn |
| Jun 30, 2025 | 8.31 Bn |
| Dec 31, 2024 | -10.00 Mn |
| Jun 30, 2024 | 7.53 Bn |
| Dec 31, 2023 | 6.18 Bn |
| Jun 30, 2023 | 8.29 Bn |
| Dec 31, 2022 | 5.93 Bn |
| Jun 30, 2022 | 7.05 Bn |
| Dec 31, 2021 | 6.30 Bn |
| Jun 30, 2021 | 9.08 Bn |
| Dec 31, 2020 | 9.79 Bn |
| Jun 30, 2020 | 8.88 Bn |
| Dec 31, 2019 | 7.03 Bn |
| Jun 30, 2019 | 7.86 Bn |
| Dec 31, 2018 | 9.68 Bn |
| Jun 30, 2018 | 9.60 Bn |
| Dec 31, 2017 | 5.31 Bn |